Dc-Cik
Small- Cell Lung Cancer
Affiliated Hospital to Academy of Military Medical SciencesCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Small- Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adenovirus-transfected autologous dendritic cell vaccine Affiliated Hospital to Academy of Military Medical Sciences | Phase 1/2 | CCC |
Same molecule, other indications
Dc-Cik is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →